Ph.D. in Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and Postdoctoral Fellow, Friedrich Miescher Institute for Biomedical Research, Switzerland
Dr. Lei Zhang has been working on molecular biology of inflammatory response, tumor neovascularization and tumor formation, and is dedicated to the R&D of cell therapies. He worked at Fosun Kite Biotechnology, where he was responsible for technology transfer of Yescarta from Kite Pharma, which was approved by the NMPA as first CAR-T product in China. He also led early development of several internal innovative CAR-T research programs for solid tumor therapy, leading to 6 patent applications. Dr. Zhang has published several papers in Nature Immunology, Cancer Research, Current Biology, among others.